Evidence map›Paper›PMID 28108885›Full record

ReviewNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2017

Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials.

Benjamin M Ellingson, Patrick Y Wen, Timothy F Cloughesy

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 312 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
312citing papers in PubMed, 8 pooled it
16.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

312 citing papers in PubMed, 8 syntheses or guidelines pooled it, 442 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Systemic Immune Correlates of Long-term Survival after Delta-24-RGD Based on the Therapeutic Adenovirus for Recurrent Glioblastoma Effect Trial (TARGET).Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Trial
  11. Trial
  12. Dual Immune Check Point Blockade inJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025
    Trial
  13. Trial
  14. Trial
  15. Response Rate and Molecular Correlates to Encorafenib and Binimetinib in BRAF-V600E Mutant High-Grade Glioma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024
    Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

252 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Benjamin M EllingsonUCLA Brain Tumor Imaging Laboratory, Center for Computer Vision and Imaging Biomarkers, University of California Los Angeles, 924 Westwood Blvd., Suite 615, Los Angeles, CA, 90024, USA. bellingson@mednet.ucla.edu.
Patrick Y WenCenter for Neuro-Oncology, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, MA, USA.
Timothy F CloughesyUCLA Neuro-Oncology Program, University of California Los Angeles, Los Angeles, CA, USA.
University of California, Los Angeles · USCenter for Neuro-Oncology · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Radiographic endpoints including response and progression are important for the evaluation of new glioblastoma therapies. The current RANO criteria was developed to overcome many of the challenges identified with previous guidelines for response assessment, however, significant challenges and limitations remain. The current recommendations build on the strengths of the current RANO criteria, while addressing many of these limitations. Modifications to the current RANO criteria include suggestions for volumetric response evaluation, use contrast enhanced T1 subtraction maps to increase lesion conspicuity, removal of qualitative non-enhancing tumor assessment requirements, use of the post-radiation time point as the baseline for newly diagnosed glioblastoma response assessment, and "treatment-agnostic" response assessment rubrics for identifying pseudoprogression, pseudoresponse, and a confirmed durable response in newly diagnosed and recurrent glioblastoma trials.

Indexed as

Magnetic Resonance ImagingBrainBrain NeoplasmsClinical Trials as TopicDisease ProgressionGlioblastomaHumansImage EnhancementImage Interpretation, Computer-AssistedTreatment OutcomeGBMGlioblastomaRANOResponse AssessmentT1 Subtraction

Identifiers

PMID28108885
PMCPMC5398984
OpenAlexW2577801124

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.